Fluoromedroxyprogesterone acetate: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
No edit summary
Line 86: Line 86:
{{Antineoplastic-drug-stub}}
{{Antineoplastic-drug-stub}}
{{dictionary-stub1}}
{{dictionary-stub1}}
{{No image}}
 
<gallery>
<gallery>
File:Fluoromedroxyprogesterone_acetate.svg|Fluoromedroxyprogesterone acetate
File:Fluoromedroxyprogesterone_acetate.svg|Fluoromedroxyprogesterone acetate
</gallery>
</gallery>

Revision as of 21:55, 16 March 2025

INN
Drug class Angiogenesis inhibitor; Progestogen; Progestogen ester; Progestin; Glucocorticoid
Routes of administration By mouth
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number 171611-77-1
PubChem 9865941
DrugBank
ChemSpider 8041632
KEGG


Fluoromedroxyprogesterone acetate (FMPA, 9α-fluoromedroxyprogesterone acetate, or 9α-FMPA) is a synthetic steroid medication which was under development by Meiji Dairies Corporation in the 1990s and 2000s for the potential treatment of cancers but was never marketed.<ref name="AdisInsight">https://adisinsight.springer.com/drugs/800011224</ref><ref name="pmid9118456">,

 Synthesis of a new potent anti-angiogenic agent, 17 alpha-acetoxy-9 alpha-fluoro-6 alpha-methylprogesterone (9 alpha-fluoromedroxyprogesterone acetate [FMPA]), 
 Chem. Pharm. Bull., 
 
 Vol. 45(Issue: 2),
 pp. 421–3,
 DOI: 10.1002/chin.199737217,
 PMID: 9118456,</ref><ref name="pmid10701698">, 
 Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate, 
 Biopharm Drug Dispos, 
 
 Vol. 20(Issue: 6),
 pp. 277–84,
 DOI: <277::AID-BDD186>3.0.CO;2-T 10.1002/(SICI)1099-081X(199909)20:6<277::AID-BDD186>3.0.CO;2-T,
 PMID: 10701698,</ref><ref name="pmid10530777">, 
 Anti-angiogenic activity of a novel synthetic agent, 9alpha-fluoromedroxyprogesterone acetate, 
 Cancer Lett., 
 
 Vol. 145(Issue: 1-2),
 pp. 107–14,
 DOI: 10.1016/S0304-3835(99)00239-6,
 PMID: 10530777,</ref><ref name="pmid10799740">, 
 Inhibition by 9alpha-fluoromedoroxyprogesterone acetate (FMPA) against mammary carcinoma induced by dimethylbenz[a]anthracene in rats and angiogenesis in the rabbit cornea - comparison with medroxyprogesterone acetate (MPA), 
 Cancer Lett., 
 
 Vol. 154(Issue: 1),
 pp. 63–9,
 DOI: 10.1016/S0304-3835(00)00375-X,
 PMID: 10799740,</ref><ref name="pmid17077554">, 
 Synthesis and anti-tumor activity of a fluorinated analog of medroxyprogesterone acetate (MPA), 9alpha-fluoromedroxyprogesterone acetate (FMPA), 
 Chem. Pharm. Bull., 
 
 Vol. 54(Issue: 11),
 pp. 1567–70,
 DOI: 10.1248/cpb.54.1567,
 PMID: 17077554,</ref><ref name="pmid17142973">, 
 Suppression of laser-induced choroidal neovascularization by subconjunctival injection of 9alpha-fluoromedroxyprogesterone acetate (FMPA), an anti-angiogenic agent, in rats, 
 Biol. Pharm. Bull., 
 
 Vol. 29(Issue: 12),
 pp. 2410–4,
 DOI: 10.1248/bpb.29.2410,
 PMID: 17142973,</ref> It is described as an antiangiogenic agent, with about two orders of magnitude greater potency for inhibition of angiogenesis than its parent compound medroxyprogesterone acetate.<ref name="pmid9118456" /><ref name="pmid10530777" /><ref name="pmid10799740" /> FMPA showed about the same affinities for the progesterone and glucocorticoid receptors as MPA.<ref name="pmid10530777" /> It reached the preclinical phase of research prior to the discontinuation of its development.<ref name="AdisInsight" />

See also

References

<references group="" responsive="1"></references>


External links




Stub icon
   This article is a  stub. You can help WikiMD by expanding it!



This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia
Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!